HC Wainwright & Co. Maintains Buy on FibroBiologics, Lowers Price Target to $4

Benzinga · 21h ago
HC Wainwright & Co. analyst Matthew Caufield maintains FibroBiologics (NASDAQ:FBLG) with a Buy and lowers the price target from $6 to $4.